Osteosarcoma medical therapy

Jump to navigation Jump to search


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammadmain Rezazadehsaatlou[2].

Osteosarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Osteosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Biopsy

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Osteosarcoma medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Osteosarcoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Osteosarcoma medical therapy

CDC on Osteosarcoma medical therapy

Osteosarcoma medical therapy in the news

Blogs on Osteosarcoma medical therapy

Directions to Hospitals Treating Osteosarcoma

Risk calculators and risk factors for Osteosarcoma medical therapy

Overview

The predominant therapy for osteosarcoma is neoadjuvant chemotherapy (chemotherapy given before surgey) followed by surgical resection. The most common drugs used to treat osteosarcoma are cisplatin, doxorubicin and high-dose methotrexate. Ifosfamide can be used as an adjuvant treatment if the necrosis rate is low. Samarium is a radioactive drug that targets areas where bone cells growing, such as tumor cells in the bone. It relieves bone pain.

Medical Therapy

The osteosarcoma treatment should be determined According to:[1][2][3][3][4][5][6][7][8]

Accordingly, up to this time the available treatment for osteosarcoma is one of a combination of the following treatments:

However, the current standard treatment for osteosarcoma is to use neoadjuvant chemotherapy (chemotherapy given before surgery) followed by surgical resection.

Chemotherapy regimens

Samarium

  • Samarium is a radioactive drug that targets areas where bone cells growing, such as tumor cells in the bone.
  • It helps relieve pain caused by cancer in the bone.
  • It also kills the blood cells in bone marrow.
  • Treatment with samarium may be followed by stem cell transplant.
  • Before treatment with samarium, stem cells (immature blood cells) are removed from the blood or bone marrow of the patient and are frozen and stored. After treatment with samarium is complete, the stored stem cells are thawed and given back to the patient through an infusion. These re-infused stem cells grow into (and restore) the body's blood cells.

References

  1. Bishop MW, Janeway KA, Gorlick R (February 2016). "Future directions in the treatment of osteosarcoma". Curr. Opin. Pediatr. 28 (1): 26–33. doi:10.1097/MOP.0000000000000298. PMC 4761449. PMID 26626558.
  2. Szewczyk M, Lechowski R, Zabielska K (March 2015). "What do we know about canine osteosarcoma treatment? Review". Vet. Res. Commun. 39 (1): 61–7. doi:10.1007/s11259-014-9623-0. PMC 4330401. PMID 25422073.
  3. 3.0 3.1 Biazzo A, De Paolis M (December 2016). "Multidisciplinary approach to osteosarcoma". Acta Orthop Belg. 82 (4): 690–698. PMID 29182106.
  4. Selmic LE, Griffin LR, Rector MH, Lafferty M, Pool R, Ehrhart NP (September 2016). "Treatment of extraskeletal osteosarcoma at a previous injection site resulting in prolonged survival in 1 dog". Can. Vet. J. 57 (9): 950–4. PMC 4982565. PMID 27587886.
  5. Swift KE, LaRue SM (March 2018). "Outcome of 9 dogs treated with stereotactic radiation therapy for primary or metastatic vertebral osteosarcoma". Vet Comp Oncol. 16 (1): E152–E158. doi:10.1111/vco.12362. PMID 29181871.
  6. Redondo A, Cruz J, Lopez-Pousa A, Barón F (December 2013). "SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013". Clin Transl Oncol. 15 (12): 1037–43. doi:10.1007/s12094-013-1087-0. PMID 23907290.
  7. Gill J, Ahluwalia MK, Geller D, Gorlick R (January 2013). "New targets and approaches in osteosarcoma". Pharmacol. Ther. 137 (1): 89–99. doi:10.1016/j.pharmthera.2012.09.003. PMID 22983152.
  8. Meyers PA (2015). "Systemic therapy for osteosarcoma and Ewing sarcoma". Am Soc Clin Oncol Educ Book: e644–7. doi:10.14694/EdBook_AM.2015.35.e644. PMID 25993235.

Template:WH Template:WS